Diabetes, Obesity and Human Reproduction

2022 Activity indicators

2 competitive national public projects: ISCIII.
1 intramural CIBERDEM led project.
1 private project led
2 competitive HR contracts
13 publications.
IF: 67,694
D1 publications: 1 (14 %)
Q1 publications: 2 (15 %)
Members of Editorial Committees: 2 PI
Evaluators of Public Agencies: 1 PI
1 European patent application EP19382836.5 with title "Combined therapy comprising an inhibitor of interleukin-17 activity and a vitamin D receptor agonist" and extension PCT/EP2020/077227.

Milestones

Award of the first R+D+I project in health to Dr. Nattero "Sexual dimorphism and inflammatory biomarkers in patients with type 1 Diabetes Mellitus and Autonomic Cardiac Neuropathy" opening a new line of research for the group (PI22/00616).
Bayona A, Martínez-Vaello V, Zamora J, Nattero-Chávez L, Luque-Ramírez M, Escobar-Morreale HF. Prevalence of PCOS and related hyperandrogenic traits in premenopausal women with type 1 diabetes: a systematic review and meta-analysis. Hum Reprod Update. 2022; 28(4):501-517. doi: 10.1093/humupd/dmac011. PMID: 35237802. The results of this meta-analysis show that one in four women with type 1 diabetes have hyperandrogenic disorders including polycystic ovary syndrome.
Luque-Ramírez M, Ortiz-Flores AE, Martínez-García MÁ, Insenser M, Quintero-Tobar A, De Lope Quiñones S, Fernández-Durán E, Nattero-Chávez ML, Álvarez-Blasco F, Escobar-Morreale HF. Effect of Iron Depletion by Bloodletting vs. Observation on Oxidative Stress Biomarkers of Women with Functional Hyperandrogenism Taking a Combined Oral Contraceptive: A Randomized Clinical Trial. J Clin Med. 2022 Jul 3;11(13):3864. doi: 10.3390/jcm11133864. PMID: 35807149. This paper presents part of the results of the ISCIII-funded randomised clinical trial (PI14/00649). The results obtained confirm that the decrease in blood donation is not associated with an improvement in the oxidative stress marker profile of these patients with functional hyperandrogenism treated with OCPs.
Publication of the results of the DIAGNODE-2 clinical trial (NCT03345004) in which Dr. Nattero participated. The results of this clinical trial demonstrate an improvement in glycaemic control after administration of intralymphatic GAD-alum in newly diagnosed T1D patients with HLA DR3-DQ2. Clin Endocrinol Metab. 2022 PMID: 35665810.
Organisation of the IV Conference on Diabetes, Obesity and Human Reproduction: update on Polycystic Ovary Syndrome (PCOS), with the participation of 2 internationally recognised researchers, Dr. Elisabet Stener-Victorin and Dr. Flaminia Faneli.

Bibliometrics

	Articles	Accum. IF	Mean IF	Articles Q1 or Q2	% in Q1 or Q2	Articles D1	% in D1
2018	17	77,06	5,14	12	71	3	18
2019	15	61,25	4,08	12	80	3	20
2020	10	44,07	4,41	9	90	1	10
2021	16	128,57	8,08	13	81	3	19
2022	13	67,69	5,21	7	53,85	1	7,69
	71	378,647	5,37	53	75,14	11	14,82